PRIMARY STUDY
Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments
Key Findings: This systematic review finds several novel symptom-specific therapeutic strategies for patients with schizophrenia. Monotherapies investigated included ulotaront, xanomeline/trospium chloride, vabicaserin, and roluperidone. Pimavanserin, bitopertin, BI 425809, encenicline, tropisetron, pregnenolone, D-serine, estradiol, tolcapone, valacyclovir, cannabidiol, and rimonabant were identified as add-on therapy.
Type of Study: Clinical Meta-analysis
Study Sample Size: 16
Study Result: Positive
Research Location(s): Canada, Germany, Japan
Year of Pub: 2024
Cannabinoids Studied: Cannabidiol (CBD), Synthetic Cannabinoid (unspecified)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Ligands Studied: Dopamine
Cannabinoid Ratio: (CBD) 0 
Additional Notes: Clinical Trial Phase I, Clinical Trial Phase II
Citation: Komatsu Y, et al. Advancements in Non-Dopaminergic Treatments for Schizophrenia: A Systematic Review of Pipeline Developments. Pharmacopsychiatry. 2024; 57:221-231. doi: 10.1055/a-2307-6484
Authors: Komatsu Y, Takehara M, Hart X, Takahashi Y, Hori S, Ueno F, Uchida H
